We are live on ! Find out more
RVM

RiverVest Venture Management Portfolio holdings

AUM $6.84M
1-Year Est. Return 7.71%
This Fund
S&P 500
This Quarter Est. Return
+38.36%
1 Year Est. Return
-7.71%
3 Year Est. Return
-16.51%
5 Year Est. Return
10 Year Est. Return
AUM
$86.1M
AUM Growth
+$18.1M
Cap. Flow
+$10.5K
Cap. Flow %
0.01%
Top 10 Hldgs %
100%
Holding
6
New
Increased
1
Reduced
Closed

Top Buys

Rank Stock Value
1
VAPO
Vapotherm, Inc. Common Stock
VAPO
+$10.5K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MIRM icon
1
Mirum Pharmaceuticals
MIRM
$6.08B
$40.4M 46.86%
1,921,118
ALLK
2
DELISTED
Allakos
ALLK
$29.9M 34.73%
4,887,932
OKUR
3
OnKure Therapeutics
OKUR
$155M
$8.07M 9.37%
240,922
XLO icon
4
Xilio Therapeutics
XLO
$59.3M
$4.2M 4.87%
102,960
SPRB
5
Spruce Biosciences
SPRB
$182M
$2.94M 3.42%
28,644
VAPO
6
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$648K 0.75%
51,570
+674
+1% +$10.5K

Similar funds

RiverVest Venture Management's Q3 2022 Portfolio in Review

As of Q3 2022, RiverVest Venture Management held 6 positions worth $86.1M, up 27% from $68M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2022: portfolio turnover was 0%. RiverVest Venture Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • RiverVest Venture Management added most to Vapotherm, Inc. Common Stock in Q3 2022, an estimated $10.5K increase.
  • RiverVest Venture Management's ten largest holdings make up 100% of its $86.1M portfolio in Q3 2022.
  • RiverVest Venture Management opened 0 new positions and closed 0 in Q3 2022.
  • RiverVest Venture Management's portfolio value rose 27% quarter-over-quarter to $86.1M.

Based on RiverVest Venture Management's 13F filing for Q3 2022, filed 14 Nov 2022.